In my cart

You have no items in your shopping cart.

RWJ 67657


Product overview

  • Name
    RWJ 67657
  • Short description
    Potent p38 MAPK inhibitor
  • Biological description
    Potent p38 MAPK inhibitor (IC50 values are 1.0 and 11 µM for p38α and β subunits respectively). Exhibits no activity at p38γ or δ subunits. Potently inhibits TNFα, IL-1β and IL-8 production (IC50 values are 15, 11 and 30 nM respectively). Also inhibits IL-6, IL-8, MMP3, COX-2 mRNA and HIV replication. Displays anti-inflammatory and cardioprotective properties. Approx 10-fold more potent than SB 203580.
  • Biological action
  • Purity
  • Citations


  • Chemical name
  • Molecular Weight
  • Molecular Formula
  • CAS Number
  • PubChem identifier
  • InChiKey

Storing and Using Your Product

  • Storage instructions
    room temperature
  • Solubility overview
    soluble in DMSO (100mM) or ethanol (50mM)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for RWJ 67657

  • Strong inhibition of TNF-alpha production and inhibition of IL-8 and COX-2 mRNA expression in monocyte-derived macrophages by RWJ 67657, a p38 mitogen-activated protein kinase (MAPK) inhibitor.

    Westra J et al (2004) Arthritis Res Ther 6(4) : R384-92.
    PubMedID: 15225374
  • RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

    Wadsworth SA et al (1999) J Pharmacol Exp Ther 291(2) : 680-7.
    PubMedID: 10525088
  • p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat.

    See F et al (2004) J Am Coll Cardiol 44(8) : 1679-89.
    PubMedID: 15489104
  • Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor.

    Muthumani K et al (2004) AIDS 18(5) : 739-48.
    PubMedID: 15075508
Support & Resources

Reviews & Product Guides